| NA (N=4) |
PPMS (N=144) |
RRMS (N=1932) |
SPMS (N=610) |
Overall (N=2690) |
|
|---|---|---|---|---|---|
| Sex | |||||
| Female | 4 (100%) | 66 (45.8%) | 1359 (70.3%) | 410 (67.2%) | 1839 (68.4%) |
| Male | 0 (0%) | 78 (54.2%) | 571 (29.6%) | 200 (32.8%) | 849 (31.6%) |
| Missing | 0 (0%) | 0 (0%) | 2 (0.1%) | 0 (0%) | 2 (0.1%) |
| Age | |||||
| Mean (SD) | 41.1 (13.8) | 50.7 (9.74) | 38.6 (10.6) | 50.4 (9.80) | 41.9 (11.6) |
| Median [Min, Max] | 39.8 [25.6, 59.1] | 51.3 [28.6, 74.7] | 38.0 [9.70, 75.1] | 50.5 [21.4, 77.7] | 41.9 [9.70, 77.7] |
| Missing | 0 (0%) | 0 (0%) | 3 (0.2%) | 0 (0%) | 3 (0.1%) |
| EDSS | |||||
| Mean (SD) | 2.00 (1.41) | 5.10 (1.85) | 1.83 (1.29) | 4.75 (1.76) | 2.68 (1.98) |
| Median [Min, Max] | 2.00 [1.00, 3.00] | 5.50 [1.00, 8.50] | 1.75 [0, 8.00] | 4.50 [0, 9.00] | 2.00 [0, 9.00] |
| Missing | 2 (50.0%) | 46 (31.9%) | 411 (21.3%) | 100 (16.4%) | 559 (20.8%) |
| BMI | |||||
| Mean (SD) | 19.8 (3.66) | 26.0 (5.46) | 25.7 (5.31) | 25.7 (6.22) | 25.7 (5.46) |
| Median [Min, Max] | 19.8 [17.2, 22.3] | 25.3 [17.9, 37.9] | 24.6 [15.8, 56.1] | 24.5 [13.7, 61.6] | 24.6 [13.7, 61.6] |
| Missing | 2 (50.0%) | 114 (79.2%) | 634 (32.8%) | 379 (62.1%) | 1129 (42.0%) |
| Center | |||||
| Gothenburg | 1 (25.0%) | 38 (26.4%) | 278 (14.4%) | 107 (17.5%) | 424 (15.8%) |
| Stockholm CFN Karolinska | 2 (50.0%) | 72 (50.0%) | 1007 (52.1%) | 364 (59.7%) | 1445 (53.7%) |
| Stockholm Danderyd | 1 (25.0%) | 6 (4.2%) | 266 (13.8%) | 55 (9.0%) | 328 (12.2%) |
| Northern | 0 (0%) | 28 (19.4%) | 381 (19.7%) | 84 (13.8%) | 493 (18.3%) |
| Previous treatment | |||||
| Interferon | 3 (75.0%) | 5 (3.5%) | 297 (15.4%) | 111 (18.2%) | 416 (15.5%) |
| treatment_naive | 1 (25.0%) | 111 (77.1%) | 733 (37.9%) | 133 (21.8%) | 978 (36.4%) |
| Dimethyl_fumarate | 0 (0%) | 3 (2.1%) | 51 (2.6%) | 25 (4.1%) | 79 (2.9%) |
| Fingolimod | 0 (0%) | 2 (1.4%) | 53 (2.7%) | 21 (3.4%) | 76 (2.8%) |
| Glatiramer_acetate | 0 (0%) | 3 (2.1%) | 56 (2.9%) | 23 (3.8%) | 82 (3.0%) |
| Natalizumab | 0 (0%) | 17 (11.8%) | 631 (32.7%) | 252 (41.3%) | 900 (33.5%) |
| Other | 0 (0%) | 1 (0.7%) | 53 (2.7%) | 21 (3.4%) | 75 (2.8%) |
| Other Anti-CD20 | 0 (0%) | 1 (0.7%) | 33 (1.7%) | 17 (2.8%) | 51 (1.9%) |
| Teriflunomide | 0 (0%) | 1 (0.7%) | 9 (0.5%) | 3 (0.5%) | 13 (0.5%) |
| Cladribine | 0 (0%) | 0 (0%) | 16 (0.8%) | 4 (0.7%) | 20 (0.7%) |
| IgG | |||||
| Mean (SD) | 9.08 (1.95) | 10.1 (2.31) | 9.86 (2.13) | 9.73 (2.30) | 9.84 (2.18) |
| Median [Min, Max] | 9.83 [6.19, 10.5] | 9.88 [5.43, 17.3] | 9.69 [4.29, 20.6] | 9.55 [2.30, 18.7] | 9.68 [2.30, 20.6] |
| Missing | 0 (0%) | 4 (2.8%) | 6 (0.3%) | 10 (1.6%) | 20 (0.7%) |
| Neutrophils | |||||
| Mean (SD) | 3.18 (0.231) | 4.50 (1.51) | 3.98 (1.23) | 4.23 (1.42) | 4.07 (1.30) |
| Median [Min, Max] | 3.15 [2.95, 3.49] | 4.33 [1.69, 10.5] | 3.82 [1.03, 12.3] | 3.99 [1.61, 15.2] | 3.87 [1.03, 15.2] |